Delivery Order SPE2DB24D2205-SPE2DB25FEFSX
- Not listed
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order valued at $1,002.64 to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Briviact 100 mg tablets (60-count units). This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 24, 2025, with performance to occur at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $5,136.01 to AmerisourceBergen Drug Corp for the supply of Briviact 50 mg tablets (60-count packaging) with a completion date of July 30, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The pharmaceutical products will be delivered to the contractor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and...
- The Defense Logistics Agency awarded a delivery order valued at $5,569.98 to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Briviact 50 mg tablets (60-count units). This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is scheduled for completion by July 28, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $5,833.23 delivery order to AmerisourceBergen Drug Corp for 60 tablets of Briviact 50 mg, with an ultimate completion date of August 1, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The work will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $6,443.28 on July 28, 2025, for the supply of Briviact 100 mg tablets in a 60-count package. This is a firm fixed-price delivery order with an ultimate completion date of July 29, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting the contractor's capability to compete in the...
- The Defense Logistics Agency awarded a delivery order valued at $1,009.45 to AmerisourceBergen Drug Corp for 60 tablets of Briviact 100 mg, a pharmaceutical product. The contract is a firm fixed price delivery order with an ultimate completion date of August 5, 2025, and was awarded on August 4, 2025. No set-aside designation was utilized in this competitive award. Performance will take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a $10,974.69 delivery order to AmerisourceBergen Drug Corp for Briviact 100 mg tablets (60-count units) under a firm fixed price contract. The award was made on August 1, 2025, with an ultimate completion date of August 4, 2025, and represents a non-competitive, non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same municipality. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Briviact 75 mg tablets (60-count units) with a ceiling value of $3,651.35. This firm fixed-price delivery order, which is expected to be completed by August 5, 2025, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting the contractor's demonstrated...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Briviact 100mg tablets (60-count packages) at a ceiling value of $3,282.79. This delivery order represents a firm fixed-price contract with no set-aside designation, executed through open competition. The order is scheduled for ultimate completion by August 27, 2025, with performance occurring at AmerisourceBergen's corporate office location in...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation. The contract is for the provision of 4,564,001,406 units of Briviact 100 mg tablets in 60-count packages. The total value of the award is $7,498.00 with a performance period through March 19, 2024. AmerisourceBergen Drug Corp is the prime contractor and no set-aside designation was used. This delivery order is a part of a larger...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEFSXDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,072.23 for Briviact 100 mg tablets (60-count) with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and reflects AmerisourceBergen's role as a critical pharmaceutical supplier within the federal medical procurement system. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The parent IDC functions as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs worldwide. AmerisourceBergen's federal contract portfolio demonstrates extensive experience fulfilling diverse pharmaceutical requirements across multiple therapeutic domains, positioning the company as a primary vendor for Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 8/1/25 |